CCN2

Across TCGA pan-cancer cohorts, CCN2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CCN2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CCN2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CCN2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

HNSC, CCRCC, and PDAC are the cancer types where CCN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	All	+0.300	.004	8	view →
CCRCC	Male	III,IV	−0.830	<.001	7	view →
PDAC	Female	All	+0.752	<.001	7	view →
LSCC	All	All	−0.236	.001	7	view →
LUAD	All	II,III,IV	−0.183	.020	2	view →
COAD	Male	II,III,IV	+1.493	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CCN2–HNSC

Open the HNSC breakdown →